ASX:CHM Chimeric Therapeutics (CHM) Stock Price, News & Analysis → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free CHM Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Chimeric Therapeutics alerts: Email Address Ad Wall Street StarAI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Chimeric TherapeuticsChimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.Read More Ad Wall Street StarAI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry CHM Stock News HeadlinesOctober 26, 2021 | proactiveinvestors.com.auChimeric Therapeutics has coverage initiated by Diamond Equity Research, attracts A$1.04 price targetOctober 25, 2021 | finance.yahoo.comDiamond Equity Research Initiates Coverage on Chimeric Therapeutics Ltd. (ASX:CHM.AX)April 30, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)October 22, 2021 | proactiveinvestors.comChimeric Therapeutics achieves first milestone towards development of CDH17 CAR TSeptember 29, 2021 | proactiveinvestors.com.auChimeric Therapeutics has CHM 1101 data accepted for prestigious Society for Neuro-Oncology annual meetingSeptember 23, 2021 | fool.com.auThe Chimeric (ASX:CHM) share price jumps 6% on patent successSeptember 23, 2021 | proactiveinvestors.com.auChimeric Therapeutics granted European patent for cancer-fighting asset CHM 1101September 15, 2021 | proactiveinvestors.com.auChimeric Therapeutics appoints experts to Cellular Immunotherapy Scientific Advisory BoardApril 30, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” September 9, 2021 | finance.yahoo.comWill Chimeric Therapeutics (ASX:CHM) Spend Its Cash Wisely?See More Headlines Receive CHM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chimeric Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:CHM CUSIPN/A CIKN/A Webwww.chimerictherapeutics.com Phone61 3 9824 5254FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,730,000.00 Net Margins-94.06% Pretax MarginN/A Return on Equity-78.65% Return on Assets-29.41% Debt Debt-to-Equity RatioN/A Current Ratio1.39 Quick Ratio2.33 Sales & Book Value Annual Sales$12.47 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares851,790,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.72 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Paul Edward-Alexander Hopper A.S.i.A (Age 68)B.A (UNSW), FAICD, Founder & Executive Chairman Comp: $250kMs. Jennifer ChowCEO, MD & DirectorMr. Eliot BourkChief Business Officer & Head of External InnovationMr. Jason B. Litten M.D. (Age 50)Chief Medical Officer Comp: $1.02MMr. Phillip Allen Hains BBus(Acc) (Age 65)C.A., M.B.A., CFO, Joint Company Secretary & Director Mr. Kelly R. Thornburg (Age 61)VP & Head of Quality Mr. Nathan Jong C.A.Company SecretaryMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersGeorge MatchamSold 1,086,956 sharesTotal: $49,999.98 ($0.05/share) This page (ASX:CHM) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaNvidia CEO Says It Will Be “the Next Revolution” Beyond AIBanyan Hill PublishingHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimeric Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
